
Conference Coverage
about 18 hours ago
Tech Offers Empathy but Digital Divide Looms in Respiratory Health CareLatest Content

Integrating Cost and Efficacy Considerations in Cancer Care: Ryan Haumschild, PharmD, MS, MBA

The Changing Treatment Landscape of IPF and PPF: Toby Maher, MD, PhD

Real-World Risks of Mavacamten Use for Obstructive Hypertrophic Cardiomyopathy

Patients Face New Care Complexities as DTC Options Expand

Louisiana Delivers Innovative Cancer Treatments, but Ensuring Access Is a Work in Progress

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

With ACA subsidies and key CMS payment models ending in 2025, premiums are set to rise, shifting costs to consumers and employers.

A study identifies tumor stage and stoma status as key drivers of diminished quality of life among patients with colorectal cancer.

While artificial intelligence showed empathy and precision in respiratory health care, its equitable adoption is paramount to prevent the widening digital divide, as highlighted at the European Respiratory Society Congress 2025.

Secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves overall survival in platinum-sensitive recurrent ovarian cancer.

This approval makes durvalumab with FLOT chemotherapy the first perioperative immunotherapy for resectable gastric or gastroesophageal junction adenocarcinoma.

A case-crossover study found that extreme heat increased mortality between 10% and 18%, with higher risks in vulnerable groups.

Non-DNMT3A CHIP subtypes raised heart failure risk in a recent analysis, offering new insights for prevention and targeted management.

US adults with arthritis have higher odds of stress, urge, and mixed urinary incontinence, highlighting the need for routine screening and integrated care.

Svetlana Barbarash, MD, outlines the lack of cardiologists and transplant services in Las Vegas and the policy changes needed to close gender gaps in care.

Onasemnogene abeparvovec-brve is now the first gene replacement therapy approved for spinal muscular atrophy in patients 2 years and older.





























































